Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Triple Negative Breast Neoplasms × parsaclisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma 2 Breast Neoplasms 2 Advanced Malignancies 2 Unresectable or Metastatic Solid Tumors 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Recurrence 1 Pancreatic Neoplasms 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 43 Cyclophosphamide 17 Paclitaxel 15 Carboplatin 15 Nivolumab 11 fludarabine 8 Specimen Handling 8 130-nm albumin-bound paclitaxel 8 Taxes 7 Magnetic Resonance Spectroscopy 7 Doxorubicin 7 Biopsy 7 spartalizumab 6 olaparib 6 durvalumab 6 atezolizumab 6 Gemcitabine 6 Cisplatin 6 veliparib 5 liposomal doxorubicin 5 budigalimab 5 Irinotecan 4 Ipilimumab 4 Fulvestrant 4 Everolimus 4 Docetaxel 4 Bevacizumab 4 trametinib 3 eribulin 3 cemiplimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04142554 2020-11-03

LCCC1820

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡